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Abstract: Despite recent advances in technology, targeting, and chemotherapy, brain metastasis 
from non-small cell lung cancer (NSCLC) remains a signiﬁ  cant problem. The vast majority of 
patients with this diagnosis undergo whole brain radiation therapy (WBRT). However, outcomes 
are still quite poor with median survivals measured in only months. In an effort to enhance 
outcomes from external beam radiation treatments, radiosensitizers have been investigated. 
Motexaﬁ  n gadolinium (MGd) (Xcytrin®, Sunnyvale, CA, USA) is a novel radiation sensitizer 
with a unique mechanism of action that may increase the therapeutic index of WBRT for 
patients with brain metastases, particularly in those with NSCLC histologies. Here we review 
the rationale for the use of this drug as well as its current and future role as a radiation enhancer 
in the management of NSCLC brain metastasis. 
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Introduction
Scope of the problem
Brain metastasis is the most common type of malignancy found in the brain, as well as 
the most frequent neurologic complication a cancer patient will encounter (Lassman and 
DeAngelis 2003). Annually, an estimated 170 000 patients develop brain metastases 
in the United States alone, most commonly presenting with headache (24%–53%), 
focal weakness (16%–40%), altered mental status (24%–31%), seizures (15%), and 
ataxia (9%–20%) (Nussbaum et al 1996; Schellinger et al 1999). The lung is the most 
common primary tumor site, with over 25% of these patients encountering brain 
metastases during the course of their illness (Sheehan et al 2002). The other most 
frequent primary tumor sites in decreasing order of incidence include breast, unknown 
primary, colorectal, melanoma, thyroid, and renal cell carcinoma (Mehta and Khuntia 
2005). Approximately 80% of these lesions occur in the cerebral hemispheres, most 
often in watershed areas between middle and posterior cerebral arteries, 10%–15% 
in the cerebellum, and 3% in the brainstem (Kufe et al 2003). 
Unfortunately, survival even in patients with the best prognostic factors is dismal, 
with untreated patients showing a median survival of only one month. To better 
characterize outcomes, the Radiation Therapy Oncology Group (RTOG) performed 
a Recursive Partitioning Analysis (RPA) on 1200 patients treated in three consecutive 
RTOG trials conducted between 1979 and 1993, analyzing a number of pretreatment 
characteristics and treatment-related variables. As a result of this analysis, patients can 
be divided into three prognostic groups using the four pretreatment factors: Karnofsky 
Performance Score (KPS), age, control of primary tumor, and presence of extra-
cranial metastases. Patients with KPS ≥ 70, age <65 years, primary tumor control, and 
no extra-cranial metastases comprise the most favorable prognostic group, RPA class I, 
with median survival of 7.1 months (Gaspar et al 1997). Patients with KPS <70 International Journal of Nanomedicine 2007:2(1)  80
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comprise RPA class III, and have the worst prognosis, with 
median survival of 2.3 months. All other patients fall into 
RPA class II, with median survival of 4.2 months (see Table 
1). Although tumor histology does not have a substantial 
impact on survival, certain primaries such as SCLC are 
much more responsive to radiation than other histologies 
such as renal cell carcinoma or malignant melanoma (Nieder 
et al 1997). 
Treatment strategies
Though several trials have demonstrated that whole brain 
radiation therapy (WBRT) effectively increases survival to 
4–6 months, little further improvement with altered fraction-
ation schedules or the addition of other sensitizers such as 
misonidazole and bromodeoxyurine has been realized (Sause 
et al 1990; Komarnicky et al 1991; Phillips et al 1995). The 
current approach to patients with brain metastases is based 
on many factors, including performance status, extent of 
disease, and the presence of single vs multiple intracranial 
lesions. Management of a single brain metastasis is largely 
based on the compelling results of two randomized trials 
conducted by Patchell and colleagues. They ﬁ  rst random-
ized 48 patients to needle biopsy plus WBRT vs surgical 
resection followed by WBRT (Patchell et al 1990). This 
trial demonstrated a dramatic beneﬁ  t in overall survival with 
resection and WBRT, 40 weeks vs 15 weeks (p < 0.01), as 
well as a statistically signiﬁ  cant improvement in local 
recurrence, 20% vs 52% (p < 0.02). In a subsequent study, 
98 patients were randomized to surgical resection with or 
without post-operative WBRT (Patchell et al 1998). Although 
the addition of radiotherapy did not impact overall survival, 
WBRT signiﬁ  cantly lowered local recurrence (10% vs 46%, 
p < 0.001), the primary endpoint, and decreased the incidence 
of neurologic death (14% vs 44%, p = 0.003).
As surgical resection for single brain metastases became 
standard treatment, investigators began exploring the role 
of stereotactic radiosurgery for these lesions. In the RTOG 
90-05 dose escalation trial, Shaw et al sought to determine 
the safety, efﬁ  cacy, and maximum-tolerated-dose of stereo-
tactic radiosurgery (SRS) in patients with recurrent primary 
or metastatic brain tumors previously treated with EBRT 
(Shaw et al 2000). No unacceptable acute toxicity levels 
were achieved with 12–24 Gy, prescribed based on size, 
demonstrating the safety of SRS within this dose range.  
Following this, the RTOG 95-08 trial was designed to 
determine the beneﬁ  t of WBRT followed by SRS boost over 
WBRT alone in patients with 1–3 brain metastases ≤4 cm in 
diameter (Andrews et al 2004). Patients were stratiﬁ  ed by 
1 vs 2–3 metastases and also by the presence of extracranial 
metastasis. This multi-institutional trial demonstrated a sur-
vival advantage with SRS boost for patients with a solitary 
brain metastasis (6.5 vs 4.9 months, p = 0.0393), as well 
as better local control at one year (82% vs 71%, p = 0.01). 
SRS boost did not provide a survival advantage overall in 
patients with multiple metastases. However, radiosurgery 
did improve survival in RPA class I patients (p = 0.0453) 
and those with NSCLC primaries (p = 0.0508) in subset 
analysis. RPA and histology were not stratiﬁ  cations of the 
trial, however.  Improvement in performance status and 
reduction in steroid use was realized in patients receiving 
SRS. As a result of these trials, RPA class I patients with 
a single brain metastasis are currently treated with surgical 
resection or SRS followed by whole-brain radiation. Most 
patients with multiple intracranial lesions are treated with 
WBRT alone, with selected patients undergoing SRS for 
possible improvement in performance status.
Radiation sensitizers
Biochemical agents that may be combined with radiotherapy 
to improve patient outcomes have been of interest to oncolo-
gists for decades. These agents provide an advantage via four 
basic mechanisms: spatial co-operation (each modality treats 
a different anatomical site), toxicity independence, protec-
tion of normal tissue, and enhancement of tumor response 
to radiation (Coleman and Mitchell 1999). The last of these, 
known as radiation sensitizers, involves the administration 
of an agent which discriminates between tumors cells and 
normal tissue, and improves the effectiveness of the targeted 
radiation. Brain metastases can be effectively targeted by 
systemic administration of these agents, as these lesions are 
characterized by upregulation of angiogenesis and neovas-
cularization, interrupting the blood–brain barrier.
Radiosensitizers fall into three major categories: 
non-hypoxic cell sensitizers, hypoxic cell sensitizers, and 
hypoxic cytotoxins. Non-hypoxic cell sensitizers, principally 
halogenated pyrimidines, are readily incorporated into the 
DNA of rapidly dividing tumors cells and weaken DNA 
Table 1 Recursive partitioning analysis (Gaspar et al 1997)
RPA I  KPS ≥70, 1° controlled, age <65, no  7.1 months
 extracranial  mets 
RPA II  Uncontrolled 1°, age ≥65,   4.2 months
 extracranial  mets 
RPA III  KPS <70  2.3 monthsInternational Journal of Nanomedicine 2007:2(1)  81
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bonds, increasing the sensitivity to ionizing radiation (Mehta 
and Khuntia 2005). Hypoxic cell sensitizers enhance tumor 
response to radiation primarily by inducing the formation and 
stabilization of toxic DNA radicals, mimicking the effects of 
oxygen (Rowinsky 1999). Tumor cells are hypoxic relative 
to surrounding normal tissue due to obstruction of blood 
ﬂ  ow, defective or inadequate angiogenesis, and outstrip-
ping of capillary blood supply from lack of cellular growth 
control. Hypoxic cell sensitizers include the nitroimidazoles, 
misonidazole, etanidazole, nimorazole, and efaproxaril (also 
known as RSR-13 [Efaproxyn™, Allos Therapeutics, Inc., 
Westminster, CO, USA]). Unfortunately, the nitroimidazoles 
are largely limited by their neurotoxicity. However, RSR-13 
is of particular interest, as recent studies have demonstrated 
its clinical utility. 
RSR-13 is a synthetic allosteric modiﬁ  er of hemoglobin 
(Hb), which decreases Hb-oxygen binding afﬁ  nity, resulting 
in increased tumor oxygen concentration in tumor cells (Stea 
et al 2006). Suh et al conducted a Phase III trial, random-
izing 538 patients with brain metastases to 30 Gy WBRT 
with supplemental oxygen with or without RSR-13 (Suh 
et al 2004). In this trial, addition of RSR-13 did not result 
in a survival beneﬁ  t overall, but did improve survival in the 
subset of patients with primary breast cancer (8.67 vs 4.57 
months, p = 0.006). As a result of this ﬁ  nding, an ongoing 
international multi-institutional phase III clinical trial looking 
at WBRT +/–RSR-13 is currently underway. 
Finally, hypoxic cytotoxins including quinone antibiotics, 
nitroaromatic compounds, and benzotriazine di-N-oxides 
have failed to demonstrated substantial clinical efﬁ  cacy. 
The ineffectiveness of many of these radiosensitizers led 
to the development of a novel hypoxic cell sensitizer and 
redox modulator, motexaﬁ  n gadolinium (MGd). Two major 
features of MGd make this agent an ideal candidate for 
radiosensitization: high electron afﬁ  nity and tumor selectivity. 
MGd may prove to have substantial clinical efﬁ  cacy as the 
utility of this agent in conjunction with radiotherapy has been 




Formally known as gadolinium texaphyrin, MGd is in a class 
of drugs known as texaphyrins. The chemical structure is 
shown in Figure 1. The chemistry of texaphyrins was ﬁ  rst 
described by Sessler and Miller as a fully aromatic porphyrin 
analog (Sessler and Miller 2000). Texaphyrins, which are 
large porphyrin-like macromolecules, form stable complexes 
with large metal cations such as gadolinium (and other lan-
thanides). These large metal cations have a very high avidity 
for accepting electrons, which allows them to disrupt the 
cancer cell at the cellular level.
Mechansim
Magda and colleagues have suggested, through in vitro 
studies, that oxidative stress caused by redox cycling is the 
mechanism by which MGd enhances the radiation response 
(Magda et al 2001). MGd is a redox active drug that has an 
exceptionally high electron afﬁ  nity. This drug preferentially 
deposits within tumor cells and catalyzes important intra-
cellular metabolites (Young et al 1994). These compounds, 
such as ascorbate, glutathione, dihydrolipoate, nicotinamide 
adenine dinucleotide phosphate, and protein thiols, are neces-
sary to maintain the appropriate energy balance necessary 
for repairing cellular radiation injury (Rowinsky 1999). In 
addition, MGd inhibits thioredoxin reductase, which is a 
crucial enzyme required to restore reducing agents back into 
the cell. By depleting the cells of energy as well as these 
protective metabolites, the cell dies. 
More recently, additional research supporting the cyto-
toxicity of MGd on tumor cells has been reported.  MGd has 
been found to increase intracellular oxygen levels in EMT6 
mouse mammary tumors (Donnelly et al 2004). Overcoming 
hypoxia will allowed the radiation damage to become “ﬁ  xed” 
so that they cannot be repaired. In another study MGd was 
found to inhibit heme oxygenase-1 (HO1). HO1 is protein 
that that typically protects a cell from oxidative stress and is 
also an antiapoptic (Evans et al 2006). Evens and colleagues 
have also showed that MGd can induce apoptosis in fresh 
malignant cells from patients with multiple myeloma (Evens 
et al 2005). Recently, MGd had been reported to disrupt the 
zinc metabolism, which is responsible for regulating cancer 
cell growth. This has shown enhanced cell killing in both 
lung cancer cell lines and B-cell hematologic malignancies 
(Lecane et al 2005; Magda et al 2005).
Pharmacokinetics and metabolism
The pharmacokinetics and metabolism of MGd is similar 
to those of other porphyrin molecules. The drug is excreted 
through the bowel, but levels in the biliary tree tend to be 
elevated (Miller et al 1999; Sessler and Miller 2000). MGd 
has linear pharmacokinetics and is cleared in plasma over 
time without buildup (Khuntia and Mehta 2004).International Journal of Nanomedicine 2007:2(1)  82
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As gadolinium is paramagnetic, magnetic resonance 
imaging (MRI) is exquisitely sensitive in depicting uptake of 
the drug. MGd selectively introduces itself into tumors and 
may be seen on MRI up to 24 hours after injection and may 
persist for months if multiple doses are delivered (Young 
et al 1994). At least 30% of enhancement has been seen 
even 5 hours after injection of MGd. 
In the original phase Ib/II trial of MGd for brain metastasis, 
a paradoxical increased number of metastasis was found 
after the introduction of the drug into the patient (Viala et al 
1999) (Figure 2). This was not due to increased number of 
metastases, but rather a higher concentration of MGd in the 
brain which allowed for increased sensitivity on MRI. Nearly 
70% of the patients in the trial had at least a 50% reduction 
in the size of the brain metastasis.
Clinical efﬁ  cacy in brain metastasis
The safety and utility of MGd in patients with brain metas-
tases was ﬁ  rst reported by Carde et al in the phase Ib/II trial 
above, combining 30 Gy WBRT with daily pre-radiation 
MGd administration (Carde et al 2001). The results showed 
a maximum-tolerated-dose (MTD) of 6.3 mg/kg, due to dose-
limiting reversible hepatotoxicity. In addition, combined 
treatment resulted in a 72% radiological response rate and 
only 12% neurologic death vs a 47% radiologic response rate 
and 33%–50% neurological death in patients treated with 
WBRT alone (30–70.4 Gy) in RTOG trials 7916, 8528, and 
8905 (Gaspar et al 1997). 
Following this trial, Mehta and colleagues randomized 
401 patients with brain metastases to 30 Gy WBRT with or 
without 5 mg/kg/day MGd and analyzed impact on survival, 
as well as neurological and neurocognitive function (NCF) 
(Mehta et al 2003). Using survival alone as the primary 
endpoint in trials for patients with brain metastases can 
be limiting, as very few novel fractionation schedules or 
radiosensitizing agents have resulted in a survival beneﬁ  t 
and many patients die from progression of systemic disease. 

















Figure 1 Chemical structure of motexaﬁ  n gadolinium.International Journal of Nanomedicine 2007:2(1)  83
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this trial, including FACT-BR, Barthel Index of Activities of 
Daily Living, specialized neurocognitive tests, and system-
atic recording of neurologic signs and symptoms, revealed 
MGd’s positive effect on neurological function and NCF, 
which have been correlated with functional independence 
and quality of life. 
The results of this trial revealed no overall difference 
in median survival (5.2 vs 4.9 months, p = 0.48) or time to 
neurologic progression (median 9.5 vs 8.3 months, p = 0.95) 
for WBRT alone vs WBRT with MGd respectively. How-
ever, patients with NSCLC did demonstrate improved time to 
neurological progression (median not reached for MGd vs 7.4 
months, p = 0.048), time to neurocognitive progression for 
memory and executive functioning (p = 0.047), and incidence 
of neurological death (36.4% vs 51.5%, p = 0.037) (Meyers 
et al 2004). In this study, NCF at baseline was predictive of 
overall survival and in concordance with previous trials, the 
combination of tumor prognostic variables and brain function 
assessments was more predictive of survival than the tumor 
variables alone. 
The correlation between neurocognitive functioning 
(NCF) and survival was further characterized in a recent 
study by Li et al (2006). The authors analyzed 208 patients 
treated with 30 Gy WBRT as part of a phase III trial (PCYC-
9801). The authors correlated the extensive neurocognitive 
assessments performed in this study with brain metastases 
volume change as documented by MRI. The results of 
this analysis showed that a “good response” on imaging 
correlated with longer median time to NCF deterioration, 
and “good responders” demonstrated signiﬁ  cantly longer 
median survival (p = 0.03). In addition, 15-month survivors 
in relation to 4-month survivors showed a greater reduction 
in cumulative brain metastases volume and had stable or 
improving NCF scores. This analysis demonstrated that the 
ability of WBRT to cause tumor shrinkage correlates with 
NCF preservation and improved survival. The extensive 
neurologic and neurocognitive testing performed in these 
two trials highlights a new endpoint which appears to have 
signiﬁ  cant clinical utility. Neurological function and NCF 
can be objectively measured and correlates with important 
established endpoints including functional independence, 
quality of life, and survival. 
There are several explanations for the greater beneﬁ  t 
achieved in lung cancer patients treated with WBRT + MGd 
patients vs patients with other primary lesions in the recent 
study by Mehta and colleagues (Mehta et al 2006). Lung 
cancer patients are more likely to present with brain metastases, 
to have smaller and isolated intracranial metastases, and to 
have had less exposure to chemotherapy (Meyers et al 2004). 
To conﬁ  rm the beneﬁ  t demonstrated in this trial, Mehta and 
colleagues recently conducted a phase III trial (known as 
the SMART study) involving non-small cell lung cancer 
(NSCLC) patients from North America (NA), Europe, and 
Australia (Mehta et al 2006). They randomized 554 NSCLC 
Before  MGd       After MGd 
Figure 2 Before and after 10 doses of motexaﬁ  n gadolinium (MGd). MRI scans; both are non-contrast MR images. Selective uptake in the brain metastases is clearly evident 
(courtesy of Minesh P Mehta, University of Wisconsin).International Journal of Nanomedicine 2007:2(1)  84
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patients to 30 Gy WBRT ±5 mg/kg/day MGd with time to 
neurological progression (TNP) as the primary endpoint. 
Overall, combination therapy did not result in a statistically 
signiﬁ  cant improvement in TNP. However, when analysis 
was limited to NA patients, WBRT with MGd signiﬁ  cantly 
improved TNP (24.2 vs 8.8 months, p = 0.004). This unex-
pected ﬁ  nding can largely be explained by one factor: time 
between diagnosis and treatment was shorter in NA (2.2 
weeks) than in Europe (6.5 weeks). This is largely due to 
a tendency to ﬁ  rst treat with chemotherapy before WBRT 
in Europe (see Tables 2 and 3). The beneﬁ  t of the addition 
of MGd in patients treated within 3 weeks of diagnosis was 
largely not observed when treatment was delayed beyond this 
point. Thus, this study suggests the beneﬁ  t of WBRT +MGd 
in lung cancer patients treated in the US and has highlighted 
the impact of other parameters (time to treatment and prior 
chemotherapy exposure) on treatment efﬁ  cacy. As a result 
of this ﬁ  nding, MGd is currently under review of the FDA 
for approval in the US for patients with brain metastases 
from NSCLC.
In response to the encouraging results of several studies 
combining WBRT and MGd, Mehta and colleagues have 
begun to investigate the utility of MGd in combination with 
additional treatment modalities, speciﬁ  cally, stereotactic 
radiosurgery (SRS). In this trial, patients with 1–4 brain 
metastases are being treated with 37.5 Gy WBRT +10 doses 
MGd 5 mg/kg/day during weeks 2 and 3, followed by SRS 
boost +MGd 5 mg/kg within 14 days of completing WBRT. 
This study is designed primarily to determine the safety and 
tolerability of this combination, and secondarily to evalu-
ate the impact of this treatment on lesion size and number, 
neurological and neurocognitive progression, and survival. 
An additional exploratory objective is evaluation of lesion 
size and number after 11 doses of MGd in comparison with 
standard contrast-enhanced MRI. The results of this trial will 
hopefully reveal yet another use for this promising agent. 
Future directions
As efﬁ  cacy has been established for patients with NSCLC 
brain metastases, future indication in other cancers where 
redox modulation plays an important role is being investi-
gated. Table 4 shows the current ongoing trials looking at 
other indications for the drug. Promising data currently exists 
for MGd in patients with glioblastoma multiforme (GBM). 
Beneﬁ  t in GBM’s from MGd may be a result of imaging 
effects, radiation sensitization effects, and also synergy 
with other drugs.
Manon and colleagues have shown that mid treatment 
MRI imaging in patients with GBM may allow for improved 
target delineation for the boost volumes (Manon et al 2004). 
This may allow for a reduction in geographic misses with 
external beam radiation.  Recent phase I and II data also show 
potential improvements in GBM patients treated with EBRT 
and MGd concurrently with approximately a 6 month gain 
in survival compared to standard controls (Woodburn 2001; 
Suh et al 2002). More recently, preclinical data suggests that 
there may be a synergistic relationship between MGd and the 
alkylating agent temozolomide (Khuntia and Mehta 2004). 
Temozolamide has recently been validated for concurrent and 
adjuvant use with radiation in patients with newly diagnosed 
GBM, portending a survival advantage of 14.6 months vs 12.1 
months (p < 0.001) (Stupp et al 2005).  Since both drugs cross 
the blood brain barrier, a synergistic response in GBM may be 
realized and is currently under active investigation.
Another avenue of exploration includes the combination 
of other drugs with MGd to further enhance MGd’s cytotoxic 
potential. An important mechanism in cell kill is via apopto-
sis. Apoptosis is mediated, at least in part, by the Akt/protein 
kinase B pathway (Franke et al 2003). Akt is an antiapoptotic 
factor that is activated by phosphorylation after the cell is 
stressed. Since the activation of Akt to pAkt involves a redox 
Table 3 Patients receiving chemotherapy as initial treatment 
for brain metastasis (courtesy of Minesh P Mehta, University of 
Wisconsin)
Country/   Patients  Treated with chemotherapy
Region/Site enrolled
   N N  %
North America  348  6  1.7
USA 185  6  3.2
Canada 163  0  0.0
Rest of world  206  36  17.5
France 117  25  21.4
Site 186  34  13  38.2
Site 211  10  2  20.0
Table 2 Distribution of patients from brain metastasis diagnosis 
to randomization (courtesy of Minesh P Mehta, University of 
Wisconsin)
  0–2 weeks   2–4 weeks   >4 weeks
  N    % N  % N    %
Overall  274    49.5% 161 29.1% 119    21.5%
North  America 208    59.8% 106 30.5% 34  9.8%
Rest of world  66  32.0%  55  26.7%  85   41.3%
France  26  22.2% 25   21.4% 66   56.4%International Journal of Nanomedicine 2007:2(1)  85
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pathway, MGd has a unique ability to potentially interrupt the 
phosphorylation and decrease the amount pAKT, which may 
be cytoprotective in the tumor cell. Ramos and colleagues 
have shown in the presence of MGd, levels of pAKT are 
initially increased and then decreased right before cell death 
(Ramos et al 2006). This initial increase may be the tumor 
cells protective response to a stress and it is postulated that 
attenuating pAKT levels may lead to a synergistic response if 
inhibitors of the Akt kinase phosphorylation process is intro-
duced in conjunction with MGd. They have found that when 
combining SH-5, an inhibitor of Akt kinase phosphorylation 
with MGd, synergistic toxicity to the cell was realized. This 
groundbreaking research may allow for the development of 
many more drugs that modulate pAkt, such as celecoxib or 
docetaxol (Ramos et al 2006). 
Finally, MGd is also being evaluated for use as an agent 
in neutron capture therapy (GdNCT). Traditionally, boron 
neutron capture therapy has only modest efﬁ  cacy in CNS 
tumors. This was largely because of a lack of tumor speciﬁ  c-
ity to the boronated compounds. By incorporating a selective 
drug like MGd, it is postulated the gadolinium neutron cap-
ture may be able penetrate tumor cells more readily. Efforts 
are currently under way to ﬁ  nd a gadolinium compound with 
high nuclear afﬁ  nity that may translate to improved tumor 
penetration (De Stasio et al 2001, 2005). 
Conclusion
MGd is a novel radiation sensitizer with a unique mechanism 
of action that has recently shown efﬁ  cacy in patients with 
NSCLC in North America. Because of its unique mechanism 
of action, its use in other diseases is actively under investiga-
tion. Synergy with other drugs remains investigational, but 
mechanistically, combination with other drugs may improve 
MGd’s cytotoxicity.
Table 4  Selected ongoing clinical trials using motexaﬁ  n gadolinium (MGd)
Trial Principal  investigator
Randomized phase III trial of Xcytrin® MGd. Injection for the   Minesh Mehta, University of Wisconsin; Paul P. Carbone Comprehensive  
treatment of brain metastases in patients with NSCLC   Cancer Center, Madison, WI; Corey Langer, Fox Chase Cancer 
undergoing whole brain radiation therapy completed.  Center, Philadelphia, PA, USA
Phase II trial of Xcytrin MGd with WBRT and SRS for patients with   Minesh Mehta, University of Wisconsin; Paul P Carbone, 
NSCLC and brain metastases  Comprehensive Cancer Center, Madison, WI, USA
Phase II Trial of Xcytrin MGd. injection for the treatment of metastatic  Robert Amato, Scott Department of Urology at Baylor College of
renal cell carcinoma  Medicine in Houston, TX, USA
A phase I/II trial of redox regulation in patients with relapsed or   Andrew Evens, Leo I Gordon, Robert H Lurie, Comprehensive Cancer 
refractory CD20 positive non-Hodgkin’s lymphoma NHL: combining   Center, Northwestern University, Chicago, IL, USA
90yttrium-zevalin and the redox-modulating agent MGd
An open-label phase II trial of MGd in patients with relapsed or   Andrew Evens, Seema Singhal, Robert H Lurie, Comprehensive Cancer 
refractory multiple myeloma   Center, Northwestern University, Chicago, IL, USA
Phase II trial of MGd in patients with relapsed or refractory indolent   Brad Kahl, University of Wisconsin Comprehensive Cancer Center, 
non-Hodgkin’s lymphoma  Madison, WI, USA
Phase II trial MGd in patients with chronic lymphocytic leukemia or   Andrew Evens, Robert H Lurie, Comprehensive Cancer Center,
small lymphocytic lymphoma with refractory or relapsed disease  Northwestern University, Chicago, IL; Neil Kay, MD, Mayo Clinic, 
  Rochester, MN, USA
Phase I trial of MGd and chemoradiation in locally advanced, squamous   Principal Investigator: David Brizel, Duke University, Durham, 
cell carcinoma of the head and neck  NC, USA
Phase I study of gadolinium texaphyrin PCI-0120. and radiotherapy in   Children’s Cancer Group
children with intrinsic pontine glioma
A phase I trial of MGd and docetaxel chemotherapy in the treatment  Gurkamal Chatta, University of Pittsburgh Cancer Institute, 
of advanced solid tumors   Pittsburgh, PA, USA
Phase I Trial of MGd and docetaxel administered at 3-week intervals  Kishan Pandya, University of Rochester Cancer Center, Rochester, 
for advanced solid tumors  NY, USA 
Phase I trial of MGd in combination with temozolomide for treatment   William R Shapiro, Barrow Neurological Institute, Phoenix, 
of malignant gliomas  AZ, USA
Phase I trial of MGd in combination with docetaxel and cisplatin   David Stewart, Anderson Cancer Center, Houston, TX, USA
for treatment of NSCLC. International Journal of Nanomedicine 2007:2(1)  86
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